Gerresheimer AG/€GXI
1D1W1MYTD1Y5YMAX
Capital at risk
About Gerresheimer AG
Gerresheimer AG is a prominent player in the healthcare and life sciences industry, specializing in the production of glass and plastic products for pharmaceutical and cosmetic packaging. The company’s key offerings include pharmaceutical vials, prefillable syringes, glass and plastic packaging for drugs, as well as delivery systems for the safe administration of medications. Founded in 1864, Gerresheimer has evolved into a global entity with headquarters in Düsseldorf, Germany, and operates manufacturing sites in Europe, the Americas, and Asia. Its strategic strength lies in a broad product portfolio and advanced technical expertise, enabling it to cater to the stringent requirements of its diverse clientele in the healthcare sector. The company’s comprehensive geographic footprint and commitment to innovation bolster its competitive position in the market.
- Ticker
- €GXI
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 13,528
- Headquarters
- Düsseldorf, Germany
- Website
- www.gerresheimer.com
Gerresheimer AG Metrics
BasicAdvanced
€950M
-
-€9.27
0.48
-
Price and volume
Market cap
€950M
Beta
0.48
52-week high
€44.88
52-week low
€14.90
Average daily volume
148K
Financial strength
Current ratio
0.81
Quick ratio
0.445
Long term debt to equity
1.445
Total debt to equity
2.08
Interest coverage (TTM)
1.07%
Profitability
EBITDA (TTM)
358.242
Gross margin (TTM)
23.62%
Net profit margin (TTM)
-13.80%
Operating margin (TTM)
4.52%
Effective tax rate (TTM)
3.46%
Revenue per employee (TTM)
€170,000
Management effectiveness
Return on assets (TTM)
1.59%
Return on equity (TTM)
-24.41%
Valuation
Price to revenue (TTM)
0.415
Price to book
0.88
Price to tangible book (TTM)
-2.7
Price to free cash flow (TTM)
-2.042
Free cash flow yield (TTM)
-48.98%
Free cash flow per share (TTM)
-13.646
Growth
Revenue change (TTM)
16.55%
Earnings per share change (TTM)
-489.32%
3-year revenue growth (CAGR)
8.50%
10-year revenue growth (CAGR)
6.11%
3-year earnings per share growth (CAGR)
44.70%
10-year earnings per share growth (CAGR)
10.82%
Bulls say / Bears say
The sale of its Centor U.S. business and global Primary Packaging Plastics unit to Apax Partners for €1.5 billion will generate substantial cash inflows, enabling Gerresheimer to significantly reduce leverage and optimize its capital structure. (Reuters)
The divestiture is set to refocus management on high-value drug delivery systems and primary injectable packaging, aligning with the CEO's strategic priority to strengthen core growth segments. (Apax Partners)
Investors responded positively to the transaction, with shares surging over 12% intraday following the announcement, reflecting market approval of the company's strategic execution. (Investing.com)
Gerresheimer cut its 2026 margin outlook on June 29, citing project delays and operational challenges in production ramp-ups, signaling execution risks that could pressure profitability. (Reuters)
In February 2026, Gerresheimer rescheduled its 2025 financial results and initiated the sale of Centor amid a BaFin probe into revenue recognition practices, heightening regulatory and governance concerns. (Reuters)
The March 10, 2026 deferral of its 2025 annual and consolidated financial statements led to its removal from the SDAX index, underscoring persistent reporting deficiencies and eroding investor confidence. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Upcoming events
No upcoming events
Funds containing Gerresheimer AG
AllEURGBPUSD
Fund name | Fund size | €GXI weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.06% |
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 0.02% |
Amundi STOXX Europe 600€MEUD | €7.6B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.